The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic SCCHN. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) was the cornerstone in the treatment algorithm. Immune checkpoint inhibitors (e.g., Keytruda, Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo) are also prescribed in later lines, where competition is fierce. Although SCCHN has historically been a complex challenge for drug developers, many immuno-oncology treatment approaches and other drug classes are in the late-phase pipeline for both metastatic and early-stage settings. Several agents are positioned to treat the untapped and lucrative locoregionally advanced SCCHN, fueling market growth over the 2020-2030 forecast period.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.